Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Reed F Beall

Showing results (21-30 of 62) with videos related to

Pageof 7
Sort By:
Drug Discovery Today|July 29, 2018
Patent term restoration for top-selling drugs in the United StatesReed F Beall, Jonathan J Darrow, Aaron S Kesselheim
Nature Biotechnology|December 9, 2017
Will inter partes review speed US generic drug entry?Jonathan J Darrow, Reed F Beall, Aaron S Kesselheim
The New England Journal of Medicine|March 14, 2019
Major Events in the Life Course of New Drugs, 2000-2016Reed F Beall, Thomas J Hwang, Aaron S Kesselheim
Journal of Pharmaceutical Policy and Practice|January 5, 2021
Repurposing existing drugs for new uses: a cohort study of the frequency of FDA-granted new indication exclusivities since 1997Babak Sahragardjoonegani, Reed F Beall, Aaron S Kesselheim, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|August 28, 2021
Reimagining Pharmaceutical Market Exclusivities: Should the Duration of Guaranteed Monopoly Periods Be Value Based?Reed F Beall, Aidan Hollis, Aaron S Kesselheim, et al.
Nature Biotechnology|April 13, 2021
Identifying potential prescription drug product hoppingVrushab Gowda, Reed F Beall, Aaron S Kesselheim, et al.
Clinical and Translational Science|May 13, 2021
The timing of 30-month stay expirations and generic entry: A cohort study of first generics, 2013-2020Sunand Kannappan, Jonathan J Darrow, Aaron S Kesselheim, et al.
Plos One|February 25, 2016
Is Patent "Evergreening" Restricting Access to Medicine/Device Combination Products?Reed F Beall, Jason W Nickerson, Warren A Kaplan, et al.
Nature Biotechnology|September 10, 2022
Brand-name market exclusivity for nebulizer therapy to treat asthma and COPDWilliam B Feldman, Doni Bloomfield, Reed F Beall, et al.
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne|June 13, 2022
COVID-19 and the prevalence of drug shortages in Canada: a cross-sectional time-series analysis from April 2017 to April 2022Brian Lau, Mina Tadrous, Cherry Chu, et al.
Pageof 7

Showing results (21-30 of 62) with videos related to

Sort By:
Pageof 7
Drug Discovery Today|July 29, 2018
Patent term restoration for top-selling drugs in the United StatesReed F Beall, Jonathan J Darrow, Aaron S Kesselheim
Nature Biotechnology|December 9, 2017
Will inter partes review speed US generic drug entry?Jonathan J Darrow, Reed F Beall, Aaron S Kesselheim
The New England Journal of Medicine|March 14, 2019
Major Events in the Life Course of New Drugs, 2000-2016Reed F Beall, Thomas J Hwang, Aaron S Kesselheim
Journal of Pharmaceutical Policy and Practice|January 5, 2021
Repurposing existing drugs for new uses: a cohort study of the frequency of FDA-granted new indication exclusivities since 1997Babak Sahragardjoonegani, Reed F Beall, Aaron S Kesselheim, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|August 28, 2021
Reimagining Pharmaceutical Market Exclusivities: Should the Duration of Guaranteed Monopoly Periods Be Value Based?Reed F Beall, Aidan Hollis, Aaron S Kesselheim, et al.
Nature Biotechnology|April 13, 2021
Identifying potential prescription drug product hoppingVrushab Gowda, Reed F Beall, Aaron S Kesselheim, et al.
Clinical and Translational Science|May 13, 2021
The timing of 30-month stay expirations and generic entry: A cohort study of first generics, 2013-2020Sunand Kannappan, Jonathan J Darrow, Aaron S Kesselheim, et al.
Plos One|February 25, 2016
Is Patent "Evergreening" Restricting Access to Medicine/Device Combination Products?Reed F Beall, Jason W Nickerson, Warren A Kaplan, et al.
Nature Biotechnology|September 10, 2022
Brand-name market exclusivity for nebulizer therapy to treat asthma and COPDWilliam B Feldman, Doni Bloomfield, Reed F Beall, et al.
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne|June 13, 2022
COVID-19 and the prevalence of drug shortages in Canada: a cross-sectional time-series analysis from April 2017 to April 2022Brian Lau, Mina Tadrous, Cherry Chu, et al.
Pageof 7